Orelabrutinib
 | |
| Clinical data | |
|---|---|
| Trade names | 宜诺凯 |
| Other names | ICP-022; ICP022 |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C26H25N3O3 |
| Molar mass | 427.504 g·mol−1 |
| 3D model (JSmol) | |
Orelabrutinib is a drug for the treatment of cancer.
In China, it is approved for patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), who have received at least one treatment in the past.[1]
Orelabrutinib is an inhibitor of Bruton's tyrosine kinase.[2]
References
[edit]- ^ Dhillon S (March 2021). "Orelabrutinib: First Approval". Drugs. 81 (4): 503–507. doi:10.1007/s40265-021-01482-5. PMID 33704654.
- ^ Deng LJ, Zhou KS, Liu LH, Zhang MZ, Li ZM, Ji CY, et al. (August 2023). "Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm study". Blood Advances. 7 (16): 4349–4357. doi:10.1182/bloodadvances.2022009168. PMC 10432605. PMID 37078706.
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |